![](https://cdn.benzinga.com/files/images/story/2024/07/12/Pfizer-shutterstock2_0.jpeg?width=1200&height=800&fit=crop)
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Thursday, Pfizer Inc PFE announced it selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024, …